HomeClinical TopicsFDA approves Lucentis to treat diabetic retinopathy

FDA approves Lucentis to treat diabetic retinopathy

On February 6, the U.S. Food and Drug Administration (FDA) expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy in patients with diabetic macular edema. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content